News & Analysis on Clinical Trial Services & Contract Research And Development
Recipharm has come to rescue of UK-based Ashton Pharma, which has been nervously awaiting to discover its fate, having spent five months in administration after its former owners Inyx Inc. suffered major financial woes.
Merck & Co. and its partner Vertex Pharmaceuticals have stopped enrolling cancer patients to the clinical trial of its aurora kinase trial after one patient suffered heart problems.
Geneart has launched the first fully on-line gene construct design and ordering system, dubbed Mr Gene, which is targeting the emerging 'low-price' segment of the synthetic biology market.
In-PharmaTechnologist.com brings you an update of pharmaceutical patent litigations.
The quest for more efficient methods of generating biofuels has been boosted by a metagenomic study of the gut bacteria that enable termites to digest wood.
FMC BioPolymer has introduced two new excipient products to the pharma market - the first in two years.
New research from Frost & Sullivan provides a snapshot of biopharma spending trends on contract research organisations (CROs), along with forecasts for industry growth.
Boehringer Ingelheim has added to its contract services with the manufacture, fill and finish capacity for drugs in prefilled syringes.